Pilot Study of Edaravone to Treat Acute Myocardial Infarction
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
Early reperfusion therapy has improved the clinical outcomes of patients with acute
myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion
injuries. There is now increasing evidence that reactive oxygen species cause reperfusion
injury. This study was designed to examine the effects of edaravone, a novel free radical
scavenger, in patients with AMI.